Obesity-related physiological changes resulted in a 32% reduction in posaconazole exposure in obese individuals compared to lean individuals due to the higher clearance of UGT substrates, while the opposite was found for the washout half-life, due to the higher distribution in adipose tissue. Here, SLC35A2 is linked to obesity due to melanocortin 4 receptor deficiency.